enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Patients push back against Novo Nordisk move to scrap an ...

    www.aol.com/news/patients-push-back-against-novo...

    Novo reported U.S. Levemir sales of 1.3 billion Danish crowns ($185 million) in 2023, less than 10% of sales in 2016, when Novo launched the higher-priced Tresiba as a successor product.

  3. Novo Nordisk faces scrutiny on Capitol Hill for pulling ...

    www.aol.com/news/novo-nordisk-faces-scrutiny...

    The Novo spokesperson said in a statement to Reuters on Friday that Levemir was not discontinued due to "success" of the company's newer medicines Wegovy and Ozempic, widely prescribed for weight ...

  4. Novo Nordisk to discontinue Levemir insulin in U.S. market - AOL

    www.aol.com/news/novo-nordisk-discontinue...

    The announcement comes eight months after Novo said it would cut U.S. list prices for several of its insulin products next year, including a 65% reduction in the list price of Levemir, in response ...

  5. Insulin detemir - Wikipedia

    en.wikipedia.org/wiki/Insulin_detemir

    Insulin detemir, sold under the brand name Levemir among others, is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes. [6] It is used by injection under the skin . [ 6 ]

  6. Insulin aspart - Wikipedia

    en.wikipedia.org/wiki/Insulin_aspart

    Insulin aspart, sold under the brand name NovoLog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [17] It is generally used by injection under the skin but may also be used by injection into a vein. [17]

  7. Lars Rebien Sørensen - Wikipedia

    en.wikipedia.org/wiki/Lars_Rebien_Sørensen

    He was CEO at Novo Nordisk from 2000 until the end of 2016 and was replaced by Lars Fruergaard Jørgensen at the beginning of 2017. [7] Sørensen took on the position as chairman of the board at Novo Nordisk Foundation on 1 July 2018. He is also the chairman of the board at Novo Holdings A/S. [8]

  8. Senate panel questions Novo Nordisk CEO over decision to ...

    www.aol.com/news/senate-panel-questions-novo...

    Novo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.

  9. AOL Mail

    mail.aol.com

    Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!